To see the other types of publications on this topic, follow the link: Tube à onde progressive.
Journal articles on the topic 'Tube à onde progressive'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Tube à onde progressive.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
BESSARD, G., G. HAW, P. BIGOTTE, R. BOSSUT, B. HAMONIC, J. N. DECARPIGNY, and C. GIANGRECO. "Modélisation d'un tube à onde progressive pour la caractérisation de matériaux acoustiques de masquage." Le Journal de Physique IV 04, no. C5 (May 1994): C5–271—C5–274. http://dx.doi.org/10.1051/jp4:1994555.
Full text
2
Hepburn, Sophie, Michael J. P. Wright, Conchita Boyder, Renee C. Sahertian, Ben Lu, Rui Zhang, Chris P. White, and Andrea R. Horvath. "Sex steroid hormone stability in serum tubes with and without separator gels." Clinical Chemistry and Laboratory Medicine (CCLM) 54, no. 9 (September 1, 2016): 1451–59. http://dx.doi.org/10.1515/cclm-2015-1133.
Full textAbstract:
Abstract Background: A pilot study showing a decrease in androstenedione concentration in serum collected into gel-containing serum tubes (STs) triggered an investigation of the effect of serum collection tube on steroid hormone stability. Methods: In the main study, two tube types were examined: BD Vacutainer® SST™II Advance and BD Vacutainer® Serum Tube. Forty-seven serum samples from apparently healthy volunteers were collected and analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for testosterone, androstenedione, 17-hydroxyprogesterone (17-OHP) (n=20); and oestradiol (n=27). Primary specimens were centrifuged once, maintained at room temperature and extracted within 2 h for day zero (d0) results. To assess stability following refrigeration (2–8 °C), aliquots were taken from the primary tube on day one (d1) and day five (d5) and analysed immediately. Differences in measurand concentration between tubes at d0 and following storage (d1 and d5) were evaluated for statistical significance. Results: There was a progressive and statistically significant decrease in androstenedione concentration from d0 to d5 (p<0.001) in the SST™II tubes. In addition, there was a statistically significant reduction in testosterone, 17-OHP and oestradiol concentrations at d5 (p<0.01). Interestingly, oestradiol and testosterone concentrations increased with time in plain STs (p<0.01). The only change likely to have a clinical impact was that of androstenedione in serum gel tubes. Conclusions: To optimise conditions and to reduce pre-analytical error we recommend the use of plain serum collection tubes for androstenedione and rapid separation of serum from cells when oestradiol and testosterone are requested.
3
Williams, B., G. Flores-Foxworth, S. Chapman, J. Romano, B. Kidd, G. Fuchs, M. Westhusin, D. Kraemer, and D. Frels. "124CRYOPRESERVATION OF WHITE-TAILED DEER (ODOCOILEUS VIRGINIANUS) SEMEN." Reproduction, Fertility and Development 16, no. 2 (2004): 184. http://dx.doi.org/10.1071/rdv16n1ab124.
Full textAbstract:
The methods for collecting and freezing deer semen have been, for the most part, limited to two species; red deer ( Cervus elaphus) and fallow deer ( Dama dama) (Asher et al., 2000 Anim. Reprod. Sci. 62, 195–211). The object of this study was to evaluate the progressive motility and effects of a thermal stress test on white-tailed deer (WTD) semen frozen in Biladyl extender (Mini Tube, Verona, WI, USA). Semen was collected by electroejaculation from WTD bucks (n=7, ages 1.5–2.5 years) during the breeding season. This trial was the second collection for one buck (#0025) and the third collection for the other 6 bucks. The bucks were immobilized with a xylazine/ketamine mixture i.m. (2mgkg−1 Vedco, Inc., St. Joseph, MO, 2.2mgkg−1 ketamine HCl, Fort Dodge Animal Health, Fort Dodge, IA, USA) and electroejaculated with a Pulsator IV unit (Lane Manufacturing, Denver, Co). Semen was extended 1:1 with Biladyl A, and then slowly cooled to 4°C. Once cooled, semen was extended with equal amounts of Biladyl part A, then part B, to a final concentration of 160×106cells/mL. The extended semen was then loaded into 0.25-cc straws, placed over liquid nitrogen (LN2) in vapors (−80°C) for 10min, and then plunged into LN2. Straws were stored in a LN2 tank for 3 months. Semen was thawed in a 38.5°C water bath for 45s, then placed in a warm test tube and incubated at 38.5°C for 5min before progressive motility was evaluated using a computer program (Sperm Vision, Mini Tube). A thermal stress test was performed by incubating thawed samples at 38.5°C for 1h. Results of the stress test were graded as either passed (progressive motility ≥50%) or failed (progressive motility<50%). Results are shown in the table below. Our results show that the protocol described above is suitable for the cryopreservation of white-tailed deer semen. These data suggest that the initial post-thaw progressive motility may not accurately represent the potential progressive motility of the spermatozoa (e.g. WTD s 0038 & 0103). Table 1 Volume collected and post thaw evaluation of white-tailed deer semen
4
Lake, Blue B., and Kenneth R. Kao. "Early Head Specification in Xenopus laevis." Scientific World JOURNAL 3 (2003): 655–76. http://dx.doi.org/10.1100/tsw.2003.54.
Full textAbstract:
The head represents the most dorsal and anterior extent of the body axis. InXenopus, the progressive determination of the head is an extremely complex process involving the activation and localized antagonism of a number of interdependent intracellular signaling pathways including the Wingless/Int-1 (Wnt), bone morphogenetic protein (BMP), and nodal-related pathways. The sequence of events that specify the head are: dorsal-ventral polarization and head organizer specification in the blastula; gastrulation; neural induction; and patterning of the anterior-posterior and dorsal-ventral neuraxes. Wnt signaling is required for the specification of the dorsal side initially but is then inhibited within the organizer once it has formed. Similarly, Wnt signaling is required along the length of the neural tube, but must be suppressed at its rostral end for normal brain development. Nodal signaling is also necessary for induction of the mesendoderm, but is subsequently suppressed in its dorsal-anterior extreme to specify head organizer. BMP signaling is required for ventral mesoderm and non-neural ectoderm, and must also be suppressed in the head organizer region and for the differentiation of the ventral midline of the neural tube. Thus, development of the head, and indeed the body plan in general, requires precisely timed and spatially restricted activation and repression of these signaling pathways.
5
Stewart, Emma, Andrew P. Prayle, Alison Tooke, Sara Pasalodos, Mohnish Suri, Andy Bush, and Jayesh M. Bhatt. "Growth and nutrition in children with ataxia telangiectasia." Archives of Disease in Childhood 101, no. 12 (August 29, 2016): 1137–41. http://dx.doi.org/10.1136/archdischild-2015-310373.
Full textAbstract:
BackgroundAtaxia telangiectasia (A-T) is a rare multisystem disease with high early mortality from lung disease and cancer. Nutritional failure adversely impacts outcomes in many respiratory diseases. Several factors influence nutrition in children with A-T. We hypothesised that children with A-T have progressive growth failure and that early gastrostomy tube feeding (percutaneous endoscopic gastrostomy, PEG) is a favourable management option with good nutritional outcomes.MethodsData were collected prospectively on weight, height and body mass index (BMI) at the national paediatric A-T clinic. Adequacy and safety of oral intake was assessed. Nutritional advice was given at each multidisciplinary review.Results101 children (51 girls) had 222 measurements (32 once, 32 twice, 24 thrice) between 2009 and 2016. Median (IQR) age was 9.3 (6.4 to 13.1) years. Mean (SD) weight, height and BMI Z-scores were respectively −1 (1.6), −1.2 (1.2) and −0.4 (1.4). 35/101 children had weight Z-scores below −2 on at least one occasion. Weight, height and BMI Z-scores declined over time. Decline was most obvious after 8 years of age. 14/101 (14%) children had a PEG, with longitudinal data available for 12. In a nested case control study, there was a trend for improvement in weight in those with a PEG (p=0.10).ConclusionsPatients with A-T decline in growth over time. There is an urgent need for new strategies, including an understanding of why growth falters. We suggest early proactive consideration of PEG from age 8 years onwards to prevent progressive growth failure.
6
Mataveia, G., S. J. Terblanche, J. O. Nöthling, and D. Gerber. "21 EFFECTS OF HETEROLOGOUS SEMEN PLASMA AND SEMEN EXTENDERS ON PROGRESSIVE MOTILITY OF FROZEN - THAWED RAM SPERM." Reproduction, Fertility and Development 17, no. 2 (2005): 160. http://dx.doi.org/10.1071/rdv17n2ab21.
Full textAbstract:
Frozen-thawed ram semen crosses the cervix poorly, necessitating laparoscopic insemination. Acceptable fertility can be achieved with frozen-thawed ram semen deposited at the external cervical opening if ram semen plasma (SP) is added (McPhie et al. 2000 14th ICAR 2, 78 abst). Homologous SP improves the fertility of frozen-thawed sperm of boars and dogs. Heterologous SP may have effects as well; the addition of bovine SP increased the ability of buffalo sperm (Syncerus caffer) to fertilize bovine oocytes in vitro (de Haas et al. 2003 Theriogenology 59, 392). The aim of the current study was to compare the effects of SP of rams (SPR), bulls (SPB), and dogs (SPD), protein-free TALP, Triladyl (Minitüb, Tiefenbach, Germany), and skim milk upon longevity and percentage of progressively motile frozen-thawed ram sperm. Three ejaculates from each of six rams (2 Dorpers, 2 Döhne merinos, and 2 merinos), aged 2–4 years, were extended in Triladyl, pooled and frozen as a single batch per ram at 200 × 106/mL in 0.25-mL straws. SPR was obtained from the same rams and SPB from 5 bulls by centrifugation, while the post-sperm fractions were collected from 5 dogs (SPD). Within a species, the SP from different donors was pooled and frozen in aliquots at −18°C. The 108 straws (6 rams, 6 diluents, 3 replicates) were thawed in random order. Once thawed, a straw was emptied into a tube with 0.85 mL of the appropriate fluid at 37°C and kept for 6 h. Percentage of progressively motile sperm was estimated at ×200 magnification immediately and 2, 4 and 6 h after thawing. One person thawed the semen and prepared motility specimens, while another performed all motility evaluations. Data were evaluated by means of repeated-measures ANOVA, with rams as subjects and time and fluid as fixed effects. Non-significant interactions were removed from the model. Means were compared by means of Bonferroni's test (P < 0.05). The model included ram, time, fluid, and ram × fluid, and time × fluid interactions, which were all significant (P < 0.01). Mean motility decreased from each time to the next and were 39.0% (0 h), 26.0% (2 h), 19.6% (4 h) and 12.6% (6 h), SEM 1.38%, n = 108. Mean motility was higher for skim milk (39.9%) than for all other fluids except Triladyl (27.7%), which was better than SPB (13.0%), whereas TALP (20.5%) and SPR (21.9%) were similar to Triladyl and SPB (n = 72, SEM 2.85%). The interactions (ram × fluid or time × fluid) were mainly due to SPD, SPR, Triladyl, and TALP, while milk resulted in the best and SPB in the lowest motility. This study shows that heat-treated skim milk maintains progressive motility of frozen-thawed ram sperm better than the SP of various species and protein-free TALP. In contrast to SPR, skim milk is known to result in poor fertility of frozen-thawed ram semen after cervical insemination. It would thus appear that maintenance of progressive motility in vitro may be a poor indicator of fertility after cervical insemination.
7
Ali, Yehia Z., Htin Aung, Nathan J. Doll, and Sorin V. Pislaru. "Post-surgical hydropneumopericardium: a case report of dramatic increase in the apparent size of pericardial effusion with positional changes." European Heart Journal - Case Reports 3, no. 4 (September 24, 2019): 1–4. http://dx.doi.org/10.1093/ehjcr/ytz160.
Full textAbstract:
Abstract Background Pneumopericardium is an uncommon clinical finding. It most commonly occurs after chest trauma but can also emerge as a complication following interventional or surgical procedures and can result in life-threatening complications. A high index of clinical suspicion should be present and once the condition is recognized, it should be managed promptly. Paucity of literature on pneumopericardium makes outlining any new case of paramount importance to emphasize the aspects of diagnosis and management of this rare condition. Case summary A 59-year-old woman with severe mitral valve and moderate tricuspid valve regurgitation underwent mitral and tricuspid valve repair with uneventful post-operative in-hospital stay. She presented 10 days after discharge with progressive shortness of breath. Chest X-ray revealed right hydropneumothorax. Transthoracic echocardiography (TTE) performed in the emergency department showed an apparently small pericardial effusion with patient in supine position; the effusion size increased substantially when imaging in left lateral decubitus, with presence of intrapericardial air bubbles. Computed tomography scan of the chest confirmed the presence of right hydropneumothorax and hydropneumopericardium, with a communicating pleuro-pericardial tract. The patient underwent chest tube placement which successfully decompressed both pleural and pericardial space. Discussion Hydropneumopericardium is a rare post-operative complication. Comprehensive TTE with imaging from multiple acoustic windows is mandatory when evaluating the extent of pericardial effusion. Presence of cardiac tamponade is crucial in determining the management plan.
8
Hénaux, C., J. F. Rouchon, and B. Nogarede. "Étude d'un actionneur piézoélectrique à onde progressive." J3eA 4 (2005): 022. http://dx.doi.org/10.1051/bib-j3ea:2005722.
Full text
9
Carwell, D. B., B. R. Scott, J. Len, H. Blackburn, K. R. Bondioli, G. T. Gentry, and R. A. Godke. "59 EFFECT OF STORAGE DURATION ON POST-THAW PARAMETERS OF BULL SEMEN." Reproduction, Fertility and Development 25, no. 1 (2013): 177. http://dx.doi.org/10.1071/rdv25n1ab59.
Full textAbstract:
It has been proposed that once good-quality sperm are collected, extended, and cryopreserved that the post-thaw quality will remain high regardless of the duration of storage. A previous study has suggested that there is no effect on post-thaw sperm motility of bovine semen stored in liquid nitrogen up to 13 years. However, no studies have reported the effect of extended storage of bovine semen in LN2. In this study, cryopreserved semen from Angus bulls (n = 25) was utilized. Time frames were assigned to each bull based on the year of collection and cryopreservation: time frame 1 (1960–1975), time frame 2 (1976–1991), and time frame 3 (1992–2006). Due to differences in packaging methods across time periods (glass ampules and plastic straws), thawing methods utilized were different and based on the packaging type. Semen packaged in glass ampules (n = 7) were thawed in a 37°C water bath for 80 s, while those in plastic straws (n = 18) were thawed in a 37°C water bath for 30 s. Once thawed all packages were wiped dry and either scribed (glass ampule) or the end cut (plastic straw) and the semen expelled into a 1.5-mL microcentrifuge tube and maintained at 37°C for evaluation. For sperm motility, a 20-µL sample was placed onto a prewarmed microscope slide for analysis. Sperm motility parameters (total motility and progressive motility) were evaluated by 2 experienced technicians and averaged. A hemocytometer was used to determine sperm concentration in a final dilution of 1 : 100. An eosin/nigrosin stain was used to determine sperm morphology. Parameters were analyzed using one-way ANOVA. There was no difference in sperm concentration between time frames 1 and 2 (53 × 106 mL–1 and 59 × 106 mL–1, respectively) or time frames 1 and 3 (53 × 106 mL–1 and 37 × 106 mL–1, respectively). However, time frame 2 exhibited a higher (P < 0.05) sperm concentration compared with time frame 3 (59 × 106 mL–1 v. 37 × 106 mL–1, respectively). There were no differences among time frames 1, 2, or 3 for total (42, 51, and 55%, respectively) and progressive sperm motility (29, 38, and 41%, respectively). Similarly, there were no differences among time frames 1, 2, and 3 for percent normal sperm (80 ± 3.6, 76 ± 5.0, and 71 ± 4.0%, respectively) and abnormal sperm (19 ± 3.6, 23 ± 5.0, and 28 ± 4.0%, respectively). Furthermore, time frames 1, 2, and 3 did not exhibit a difference in primary (9 ± 2.5, 7 ± 2.6, and 6 ± 1.0%, respectively), secondary (2 ± 0.8, 5 ± 1.4, 6 ± 2.0%, respectively), or tertiary abnormalities (7 ± 2.4, 10 ± 2.7, and 16 ± 2.7%, respectively). These data suggest that once good-quality bovine sperm is cryopreserved, the duration of storage (up to 43 years) has no effect on Angus bull post-thaw semen parameters.
10
Post, Stephen G. "Tube Feeding and Advanced Progressive Dementia." Hastings Center Report 31, no. 1 (January 2001): 36. http://dx.doi.org/10.2307/3528732.
Full text
11
Giraud, Frédéric, Betty Semail-Lemaire, and Jean-Paul Hautier. "Modèle dynamique d’un moteur piézoélectrique à onde progressive." Revue internationale de génie électrique 4, no. 3-4 (December 30, 2001): 411–30. http://dx.doi.org/10.3166/rige.4.411-430.
Full text
12
PÉPIN, H., and T. M. PHAN. "CALIBRATION DE SONDE INTENSIMÉTRIQUE EN TUBE À ONDE STATIONNAIRE." Le Journal de Physique IV 02, no. C1 (April 1992): C1–431—C1–434. http://dx.doi.org/10.1051/jp4:1992192.
Full text
13
HAW, G., P. BIGOTTE, J. N. DECARPIGNY, and M. RICHARD. "UTILISATION D'UN TUBE À ONDES PROGRESSIVES POUR LA DÉTERMINATION DU DIAGRAMME DE DIRECTIVITÉ D'HYDROPHONES DE PETITE TAILLE." Le Journal de Physique Colloques 51, no. C2 (February 1990): C2–1299—C2–1302. http://dx.doi.org/10.1051/jphyscol:19902305.
Full text
14
Liu, Guochen, Jihong Liu, Bingna Xian, Jing Li, Yanling Feng, He Huang, Ting Wan, et al. "Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e17532-e17532. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e17532.
Full textAbstract:
e17532 Background: Patients with platinum-resistant ovarian cancer have a poor prognosis. Effective treatment options for these patients are limited. Combination of PARP inhibitors and antiangiogenic therapy is reported as an effective antitumor strategy. In this study (ANNIE), we evaluate the activity of niraparib combined with anlotinib in patients with platinum resistant recurrent ovarian carcinoma. Methods: The ANNIE trial (ClinicalTrials.gov identifier NCT04376073) was a multicentre, single-arm, phase 2 study that evaluated the safety and activity of niraparib combined with anlotinib in patients (≥18 & ≤70 years, an Eastern Cooperative Oncology Group performance status of 0 or 1) with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer cancer whose disease recurred in less than 6 months after the last administered platinum therapy, and with measurable disease according to the Response Evaluation Criteria in Solid Tumors. Patients received oral niraparib 300mg/200mg once daily continuously and anlotinib 12mg (The initial dose was reduced to 10mg on November 1, 2020) on day 1-14 of each 21-day cycle thereafter until disease progression or intolerable toxicity. The primary objective was to assess objective response rate (ORR; complete plus partial responses) according to RECIST version 1.1. 40 cases are planned to be enrolled. Results: Between May 22, 2020 and February 6, 2021, we enrolled 33 patients (median age, 56 years [range, 37-69 years]). Patients had received a median of six (range, 2-9) previous lines of therapy. The cut-off date of analysis was February 4, 2021, the median follow-up was 4.1 months (range, 0.1–8.1). At data cutoff, all but seven (2 voluntarily withdrew, 5 with progressive disease) of the patients were still on treatment. Twenty-five patients underwent imaging evaluation. The confirmed best overall response assessment showed 12 with partial responses, 12 with stable disease, yielding the ORR of 48.0% (95% CI, 27.0%̃69.0%). The median duration of response and the median PFS were not reached. Drug-related grade 3 or worse treatment-emergent adverse events were occurred in 39.4% patients, including hand-foot skin reaction (3 pts), thrombocytopenia (2 pts), hypertriglyceridemia (2 pts), neutropenia (2 pts), anemia (1 pts) and hypertension (1 pts). The most common treatment emergent adverse events were hand-foot skin reaction (36.4%), hypertension (36.4%), and thrombocytopenia (33.3%). No treatment-related death was recorded. Enrollment was ongoing so far. Conclusions: Niraparib in combination with anlotinib showed promising antitumor activity and tolerable toxicity in patients with platinum resistant recurrent ovarian cancer. The conclusion can be clarified after the research is completed. Clinical trial information: NCT04376073.
15
Dai, Zheng, Frédéric Giraud, and Betty Lemaire-Semail. "Modélisation globale de l'interface mécanique d'un actionneur piézoélectrique à onde progressive." European Journal of Electrical Engineering 13, no. 3 (June 30, 2010): 261–82. http://dx.doi.org/10.3166/ejee.13.261-282.
Full text
16
Chen, Xingxing, Wei Xie, Yunfeng Xiao, Yiguang Chen, and Xianjie Li. "Progressive Collapse Analysis of SRC Frame-RC Core Tube Hybrid Structure." Applied Sciences 8, no. 11 (November 20, 2018): 2316. http://dx.doi.org/10.3390/app8112316.
Full textAbstract:
Steel reinforced concrete (SRC) frame-reinforced concrete (RC) core tube hybrid structures are widely used in high-rise buildings. Focusing on the progressive collapse behavior of this structural system, this paper presents an experiment and analysis on a 1/5 scaled, 10-story SRC frame-RC core tube structural model. The finite element (FE) model developed for the purpose of progressive collapse analysis was validated by comparing the test results and simulation results. The alternate load path method (APM) was applied in conducting nonlinear static and dynamic analyses, in which key components including columns and shear walls were removed. The stress state of the beams adjacent to the removed component, the structural behavior including inter-story drift ratio and shear distribution between frame and tube were investigated. The demand capacity ratio (DCR) was applied to evaluate the progressive collapse resistance under loss of key components scenarios. The results indicate that the frame and the tube cooperate in a certain way to resist progressive collapse. The core tube plays a role as the first line of defense against progressive collapse, and the frame plays a role as the second line of defense against progressive collapse. It is also found that the shear distribution is related to the location of the component removed, especially the corner column and shear walls.
17
Font Pous, Albert, Miguel Angel Climent Duran, Ignacio Duran, Begona Mellado, Jesus Paramio, Francisco X. Real, Jose Luis Ramirez, Juan Luis Sanz, and Daniel E. Castellano. "A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma." Journal of Clinical Oncology 37, no. 7_suppl (March 1, 2019): TPS501. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.tps501.
Full textAbstract:
TPS501 Background: Niraparib (N) is an orally selective poly(ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of patients (pt) with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after complete or partial response to platinum-based chemotherapy (CT). Cabozantinib (C) is a tyrosine kinase (TK) inhibitor with activity against TKs including VEGFR2, MET and AXL, approved on kidney cancer pt after TK failure, that has demonstrated clinical activity in heavily pretreated, advanced UC pt. c-Met receptor TK is activated in urothelial carcinoma (UC) cells. c-Met activity can decrease response to PARP inhibitors, whereas treatment with c-Met inhibitors renders cells more sensitive to PARP inhibition. UC pt with tumors overexpressing c-Met may benefit from the combination of c-Met and PARP inhibitors. This multicenter, open-label phase (ph) I-II study is to explore the maximum-tolerated dose (MTD) of N + C combination in pt with advanced genitourinary malignancies (UC and kidney cancer) follow by a preliminary efficacy of the combination in advanced UC. Methods: Eligible pt have confirmed histopathology of UC or clear cell renal cell carcinoma, advanced or metastatic disease, age ≥18 years, ECOG PS ≤1, progressive disease after platinum-based CT, measurable lesions, no prior therapy with PARP or c-Met inhibitors and adequate bone marrow, liver and renal functions. The ph I portion is enrolling ≈24 pt to identify the MTD proposed to use in a ph II (RP2D). Pt will receive N and C p.o. once daily in 28-day cycles: Dose level 1 (DL1) N/C 100/20 mg; DL2 200/20 mg; DL3 200/40 mg; DL4 200/60 mg. Pt will be accrued to each dose level in cohorts of 6 pt until the MTD is achieved (the highest dose at which ≤1 out of 6 pt experience a dose-limiting toxicity [DLT]). DLT will be evaluated during the first 2 cycles. The ph 2 portion will enroll 51 UC pt to receive the RP2D. Tumor response will be assessed per RECIST v1.1. Endpoints of the ph 2 are 6-month PFS (primary), overall response rate, disease control rate, duration of response, PFS and OS. Tissue and plasma sample will be collected for translational study. Clinical trial information: NCT03425201.
18
Morris, Linda L., Erik McIntosh, and Andrea Whitmer. "The Importance of Tracheostomy Progression in the Intensive Care Unit." Critical Care Nurse 34, no. 1 (February 1, 2014): 40–48. http://dx.doi.org/10.4037/ccn2014722.
Full textAbstract:
A plan to progress a tracheostomy toward decannulation should be initiated unless the tracheostomy has been placed for irreversible conditions. In most cases, tracheostomy progression can begin once a patient is free from ventilator dependence. Progression often begins with cuff deflation, which frequently results in the patient’s ability to phonate. A systematic approach to tracheostomy progression involves assessing (1) hemodynamic stability, (2) whether the patient has been free from ventilator support for at least 24 hours, (3) swallowing, cough strength, and aspiration risk, (4) management of secretions, and (5) toleration of cuff deflation, followed by (6) changing to a cuffless tube, (7) capping trials, (8) functional decannulation trials, (9) measuring cough strength, and (10) decannulation. Critical care nurses can facilitate the process and avoid unnecessary delays and complications.
19
Bigot, S., M. Kamarei, and M. Bouthinon. "Utilisation d'une onde progressive de surface pour tableau graphique de grandes dimensions." Revue de Physique Appliquée 23, no. 7 (1988): 1257–63. http://dx.doi.org/10.1051/rphysap:019880023070125700.
Full text
20
-LEBERER, Ralf. "Une nouvelle antenne plane à onde progressive à caractéristiques de rayonnement omnidirectionnel." Revue de l'Electricité et de l'Electronique -, no. 06 (2005): 44. http://dx.doi.org/10.3845/ree.2005.125.
Full text
21
Piécourt, E., and B. Nogarède. "Caractérisation électromécanique et alimentation électronique d'un moteur piézo-électrique à onde progressive." Journal de Physique III 5, no. 6 (June 1995): 689–702. http://dx.doi.org/10.1051/jp3:1995155.
Full text
22
Glen, H., D. Boss, T. R. Evans, M. Roelvink, J. M. Saro, P. Bezodis, W. Copalu, A. Das, G. Crosswell, and J. H. Schellens. "A phase I dose finding study of E7080 in patients (pts) with advanced malignancies." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 14073. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14073.
Full textAbstract:
14073 Background: E7080 is a potent inhibitor of the split-kinase family of transmembrane growth factor receptors including Flt-1 and KDR. In addition, E7080 also potently inhibits FGFR1 and PDGFRβ tyrosine kinase activities. In an in vitro angiogenic model, E7080 inhibited VEGF-driven umbilical vein endothelial cell (HUVEC) proliferation and tube formation. Using H460 and Colo205 mouse xenograft models, E7080 significantly inhibited tumor growth at doses from 1 to 100 mg/kg. Methods: A Phase I and pharmacologic study was conducted to determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of E7080 in pts with advanced malignancies. Eligible pts with adequate hematologic, renal and hepatic function, and with tumors refractory to standard therapies, were treated with E7080 administered orally on a once daily continuous dose schedule in cycles of 4 weeks. Dose escalation was performed according to an accelerated design of 100% dose increases in subsequent cohorts until the first patient experienced ≥ CTC grade 2 toxicity. Results: As of November 17th, 2006, 37 pts with documented progressive disease (PD) have been treated at the following dose levels: 0.2 mg/d, 0.4 mg/d, 0.8 mg/d, 1.6 mg/d, 3.2 mg/d, 6.4 mg/d, 12.5 mg/d and 16 mg/d. Median number of cycles was 1 (0–11). Median age = 60 years (25–84), 20 pts were male, 17 were female. 37 pts were evaluable for toxicity. 1 patient experienced grade 3 hypertension (DLT) in the 16 mg/d cohort, other related toxicities ≥ grade 2 include hemorrhage and thrombosis (n=1), tachycardia (n=1), febrile neutropenia (n=1), proteinuria (n=1), thrombocytopenia (n=1) and hypertension (n=1). MTD has not been reached and this study is continuing to recruit. 24 pts were evaluable for efficacy, 3 are too early to evaluate. 1 patient had a partial response (high grade sarcoma) after 2 cycles, and 15 pts experienced stable disease from 2+ to 11 months, and 11 pts continue on therapy. Pharmacokinetic (PK) studies: preliminary data suggest that the PK is linear over the range 0.2 mg/d to 12.5 mg/d. Conclusions: E7080 is safe and well tolerated at doses acheived so far and has shown promising first signs of anti-cancer activity associated with potent activity in pre-clinical models. Clinical and PK data from subsequent doses and follow- up will be presented. No significant financial relationships to disclose.
23
Buchman, Craig A., J. Douglas Swarts, James T. Seroky, Nicholas Panagiotou, Frederick Hayden, and William J. Doyle. "Otologic and Systemic Manifestations of Experimental Influenza a Virus Infection in the Ferret." Otolaryngology–Head and Neck Surgery 112, no. 4 (April 1995): 572–78. http://dx.doi.org/10.1177/019459989511200411.
Full textAbstract:
In an effort to further validate an animal model and to better define the mechanisms relating viral upper respiratory tract infections and acute otitis media, we infected 10 ferrets intranasally with influenza A virus. Infection was monitored by cultures and antibody titers, illness was monitored by signs and temperatures, and otologic complications were monitored by otoscopy, tympanometry, and eustachian tube function testing. All animals became infected. Forced-response test results showed progressive increases in the passive function variables after inoculation. Inflation-deflation test results documented progressive impairment of active tubal function, which was accompanied by the development of middle ear underpressures. No otitis media was seen. The results suggest that influenza A virus infection results in progressive, subtotal occlusion of the eustachian tube lumen, which compromises the ventilatory function of the tube, thereby promoting the development of middle ear underpressures. These findings support the hypothesized pathophysiologic relationship between viral upper respiratory tract infections, eustachian tube dysfunction, middle ear underpressures, and acute otitis media. Given these pathophysiologic changes and previously documented physiologic similarities to the eustachian tube-middle ear system of human beings, we conclude that the ferret represents an appropriate animal model for studying the pathogenic processes related to viral upper respiratory tract infections, eustachian tube dysfunction, and otitis media and for testing of potential prophylactic and therapeutic regimens.
24
Karbhari, Vistasp M. "Progressive Crush of Resin Transfer Molded Square Tube Stiffened Beam Elements." Journal of Composite Materials 31, no. 10 (May 1997): 981–1001. http://dx.doi.org/10.1177/002199839703101002.
Full text
25
Soebijantoro, Iwan, and Nina Asrini Noor. "Tube Length Adjustment and Tube Trimming Technique in Refractory Glaucoma." Case Reports in Ophthalmological Medicine 2020 (June 22, 2020): 1–6. http://dx.doi.org/10.1155/2020/8889448.
Full textAbstract:
Secondary glaucoma may develop after vitreoretinal surgery as it is a known risk factor for its development. When the risk factors are more than one, for instance along with neovascular glaucoma (NVG), the secondary glaucoma may become recalcitrant and very difficult to manage. Surgical intervention is often warranted to control intraocular pressure (IOP) and prevent progressive glaucomatous damage in patients with refractory glaucoma, and glaucoma drainage implant may be preferred as the primary choice. We describe a patient who develop secondary glaucoma after vitrectomy and silicone oil (SO) injection due to unresolved vitreous hemorrhage in proliferative diabetic retinopathy (PDR) and subsequent NVG. Baerveldt glaucoma implant (BGI) was carried out and placed in the superotemporal quadrant with longer anterior chamber tube placement to prevent escape of SO through the tube. Qualified success was achieved with additional one fixed-drug combination (FDC). However, 3 years later, the tube was blocked by the iris tissue at the inferior edge of the pupil. Tube trimming was performed efficiently using a simple technique. The distal end of the tube was pulled out of the anterior chamber through a paracentesis just next to the tube entrance and trimmed to the appropriate length. More than a year after the surgery, IOP was still well controlled with the same FDC. Unfortunately, the visual acuity could not be recovered due to advanced PDR.
26
Le Moal, P., P. Minotti, A. Ferreira, and J. Duffaud. "Moteurs piézo-électriques à onde progressive : II. Modélisation analytique bidimensionnelle du contact stator/rotor." Journal de Physique III 6, no. 10 (October 1996): 1339–61. http://dx.doi.org/10.1051/jp3:1996190.
Full text
27
Cheng, Tracy Z., and David M. Kaylie. "Recurrent and Progressive Facial Baroparesis on Flying Relieved by Eustachian Tube Dilation." Annals of Otology, Rhinology & Laryngology 128, no. 8 (March 21, 2019): 778–81. http://dx.doi.org/10.1177/0003489419839085.
Full textAbstract:
Objectives: Facial baroparesis is a rare phenomenon of seventh cranial nerve palsy traditionally reported in divers, with only 11 cases reported in aviation so far. It is important to correctly diagnose facial baroparesis given the differential diagnosis of stroke and decompression disease and offer appropriate treatment for recurrent cases. Methods: The authors present the case of a patient with recurrent and progressive facial baroparesis treated with Eustachian tube balloon dilation. Institutional medical records were reviewed, and analysis of the current literature was performed. Results: A 37-year-old woman experienced recurrent and progressive left facial paralysis on descent from altitude on commercial airline flights, with resolution between flights. The patient flew frequently for work-related trips and for the past 7 years had noted facial paralysis that began with mild asymmetry of the face and progressed to an inability to close her left eye. She denied any otologic symptoms other than ear fullness and pressure causing left otalgia. The right side was not involved. After treatment with Eustachian tube dilation, the patient has been on numerous flights with complete resolution of symptoms. Conclusions: This study presents a rare case of facial baroparesis on commercial flight descent that resolved after left Eustachian tube dilation. Although unilateral facial palsy can be concerning for stroke, a history of ear fullness and pressure may suggest facial baroparesis instead. For recurrent and progressive cases, Eustachian tube dilation should be considered for treatment.
28
Roslan, Mohd Nazrul, Mohd Yazid Yahya, Zaini Ahmad, Azrin Hani Abdul Rashid, and Wen Xue Wang. "Energy Absorption Capacity of Basalt Sandwich Composite Cylinder Subjected to Axial Compression Loadings." Materials Science Forum 917 (March 2018): 7–11. http://dx.doi.org/10.4028/www.scientific.net/msf.917.7.
Full textAbstract:
In this report presented the investigation of axial progressive compression on sandwich composite cylinder made from basalt fibre reinforced composite tube as skins and polyurethane (EPU) foam as core of the structure. The effect of braid orientation angle of the sandwich skins and foam core thickness were evaluated on the parameter performance namely peak force, average force, total energy absorption, crush force efficiency, and specific energy absorption. The primary failure mode observed was progressive failure fibre cracking and tube’s wall folding and crumping. Experiment result showed that the effect of outer wall braid angle of sandwich tube structure was the dominant factor contributed to high energy absorption capacity. Furthermore, the foam thickness has no significant influences on the SEA value; however, the total diameter size of sandwich tube skins was.
29
Steinwolf, Alexander, Robert G. White, and Howard F. Wolfe. "Simulation of jet-noise excitation in an acoustic progressive wave tube facility." Journal of the Acoustical Society of America 109, no. 3 (March 2001): 1043–52. http://dx.doi.org/10.1121/1.1344159.
Full text
30
Herrero Ruiz de Loizaga, Francisco Javier. "El conector ilativo-consecutivo onde en el español medieval = The illative-consecutive connector onde in Medieval Spanish." Estudios Humanísticos. Filología, no. 40 (December 19, 2018): 193. http://dx.doi.org/10.18002/ehf.v0i40.5477.
Full textAbstract:
<p><em>Onde</em> como conector ilativo-consecutivo continúa el empleo desarrollado por UNDE en el latín tardío y medieval, y se halla preferentemente en textos o fragmentos expositivo-argumentativos, en buena medida como consecuencia de una imitación culta de estos usos latinos. A pesar de su intensidad de empleo durante la Edad Media, su preferencia por determinados contextos en los que tiende a especializarse y la progresiva desaparición de <em>onde</em> como adverbio relativo e interrogativo y su consideración de vulgarismo en este empleo a partir del siglo XVI determinarán la desaparición de este conector, ya desusado en el español clásico.</p><p>Onde as consecutive connector continues the use developed by UNDE in Late and Medieval Latin, and<br />it is found mainly in expositive-argumentative texts or fragments, largely as a consequence of learned<br />imitation of these Latin uses. Despite its intense use during the Middle Ages, its preference for certain<br />contexts in which it tends to specialize and the progressive disappearance of onde as relative and interrogative adverb and its consideration of vulgarism in this adverbial use from the sixteenth century on<br />will determine the disappearance of this connector, already obsolete in classical Spanish.<br /><br /></p>
31
Ferris, R. L., S. S. Agarwala, E. Cano, D. E. Heron, J. Johnson, E. Myers, V. Sandulache, Y. Wang, S. Bahri, and A. Argiris. "Long-term outcomes with concurrent carboplatin, paclitaxel, and radiation therapy in locally advanced, inoperable head and neck cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 6032. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.6032.
Full textAbstract:
6032 Background: Our goal was to evaluate long-term outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) treated with carboplatin, paclitaxel, and radiotherapy. Methods: We conducted a phase II trial in inoperable patients with locally advanced SCCHN. Carboplatin 100 mg/m2 and paclitaxel 40 mg/m2 were administered intravenously once a week during external beam radiotherapy (once daily, 180 cGy/fraction) for 6–7 weeks. Interstitial brachytherapy was used as a boost in selected patients with primary malignancies of the oral cavity and the oropharynx. Results: 55 patients were enrolled. 52 patients (95%) had stage IV and 51 (93%) had technically unresectable disease; 62% had an oropharyngeal primary site. 21 patients underwent brachytherapy boost. Grade 3 or 4 mucositis occurred in 30% of patients. One death occurred during treatment; it was related to complications of gastrostomy tube (G-tube) placement. Forty of 50 evaluable patients (80%) had an objective response, with a complete response rate of 52%. With a median follow-up of 69 months years for surviving patients, the 5-year progression-free survival (PFS) was 36% and the 5-year overall survival (OS) was 35%. Two of the 18 long-term survivors of >50 months were G-tube feeding dependent. Patients undergoing brachytherapy boost (n=21) had similar outcomes compared with the rest of the patients. In multivariate analysis, baseline hemoglobin levels and N stage were predictive of survival. Conclusion: Treatment with concurrent carboplatin, paclitaxel and radiation is safe and offers curative potential for poor prognosis patients with locally advanced SCCHN. No significant financial relationships to disclose.
32
Yamashita, Minoru, and Toshio Hattori. "Onset of Progressive Buckling by Inertia Force in Axial Impact of Straight and S-Curved Square Tubes." Advanced Materials Research 445 (January 2012): 847–52. http://dx.doi.org/10.4028/www.scientific.net/amr.445.847.
Full textAbstract:
For the improvement of the deformation characteristic and the energy absorption efficiency of the tubular structure at impact event, a method generating the first buckling lobe using the inertia force was investigated. The solid block was attached to the wall so that its inertia force causes the partial plastic deformation that plays a role of the trigger of progressive buckling at the beginning of impact. Drop-weight impact experiment revealed that the onset of progressive buckling was achieved at the desired portion by the method. To increase the variety of tube shapes, numerical examination was conducted with the dynamic explicit finite element method. Long straight and S-curved tubes, which have square cross-section, were numerically modeled with shell elements. They were assumed to be impacted to the rigid wall to estimate the dynamic collapse behavior. The first buckling lobe generated by inertia force was demonstrated for the straight tube. The S-curved tube exhibited a bending collapse mode without the method. However, such mode was avoidable by applying the method. Then the energy absorption efficiency of the tube was drastically increased.
33
Pandey, Sanjay Kumar, and Amirlal Singh. "Peristaltic transport in an elastic tube under the influence of dilating forcing amplitudes." International Journal of Biomathematics 13, no. 04 (April 16, 2020): 2050027. http://dx.doi.org/10.1142/s1793524520500278.
Full textAbstract:
We investigate flow through an elastic tube which is constrained to a prescribed external forcing consisting of a progressive travelling wave. Such a flow dynamics is closely related to that in the oesophageal tube. The mechanics of the tube is characterized by a relationship between transmural pressure difference and radial variation of the tube. Dimensionless radial variation, assumed to be small, is studied by perturbation techniques. Results demonstrate that the elasticity of the tube plays a significant role in the flow dynamics. An increment in the forcing amplitude of the inward radial force enhances pressure, time-averaged volume flow rate and hence axial and radial velocities. It is revealed that the elastic nature of the oesophageal tube favors swallowing.
34
Yokoyama, Atsushi, and Motoharu Tateishi. "Numerical Simulation Technique for Progressive Crushing Behavior of FRP Tube under Impact Loading." Key Engineering Materials 177-180 (April 2000): 327–32. http://dx.doi.org/10.4028/www.scientific.net/kem.177-180.327.
Full text
35
Kai, Hu. "Application of Progressive Collapse Analysis in a High-Rise Frame-Core Tube Structure." American Journal of Civil Engineering 4, no. 3 (2016): 111. http://dx.doi.org/10.11648/j.ajce.20160403.18.
Full text
36
Chen, Dong, Kewei Ding, and Xiping He. "Force Mechanism and Progressive Collapse of Steel Tube-coupler Scaffold Under Local Load." KSCE Journal of Civil Engineering 22, no. 7 (September 15, 2017): 2344–53. http://dx.doi.org/10.1007/s12205-017-1022-y.
Full text
37
Yevtushenko, I. D., and S. V. Rybnikov. "Endosurgical treatment techniques of progressive tubal pregnancy." Bulletin of Siberian Medicine 5, no. 1 (March 30, 2006): 73–75. http://dx.doi.org/10.20538/1682-0363-2006-1-73-75.
Full textAbstract:
Research purpose: to increase the efficiency of endosurgical treatment of women with progressive tubal pregnancy. Research method: prospective analysis. Research subjects: in 75 female patients, to whom salpingotomy and salpingorrhaphy had been per-formed, tubal patency was found; in 10% - tubal patency was laboured; in 9,5% of patients there was an obstruction. In 52,9% of women, to whom salpingotomic orifice was not sutured, tubal patency was found; in 32,4% of patients tubal patency was disturbed; in 14,7% the fallopian tube was obstructed and in 17,6% of patients tubo-peritoneal fistula formed. Uterine pregnancy rate of salpingotomy and salpingorrhaphy - 34,1%, of women, to whom salpingotomic orifice was not sutured - 20,6%. Performance of endoscopic salpingotomy with suture of the defect at isthmial and ampullar location of the fetal ovum helps to increase the efficien-cy of surgical treatment of the ectopic pregnancy.
38
Rabb, Craig H., J. Gordon McComb, Corey Raffel, and J. Gerald Kennedy. "Spinal arachnoid cysts in the pediatric age group: an association with neural tube defects." Journal of Neurosurgery 77, no. 3 (September 1992): 369–72. http://dx.doi.org/10.3171/jns.1992.77.3.0369.
Full textAbstract:
✓ Between 1979 and 1991, spinal arachnoid cysts were found in 11 patients aged 19 months to 18 years (mean age 5½ years). Of the 11 patients, six had a myelomeningocele and one diastematomyelia. The presenting symptoms included radicular pain (one patient), progressive weakness (three), increasing scoliosis (one), worsening spasticity (three), and recurrent urinary tract infections and progressive constipation (one). Two patients showed no symptoms from the spinal arachnoid cyst. The distribution of lesions was as follows: cervicomedullary (one patient), cervical (one), cervicothoracic (two), thoracic (four), lumbar (two), and sacral (one). Four of the 11 arachnoid cysts (all intradural) were located anterior to the spinal cord, three of which were in children with a myelomeningocele. Only two of the cysts were extradural; both were found in the lumbosacral region, and one was associated with diastematomyelia. Eight patients were treated with fenestration and/or resection of the cyst wall. Three patients with anterior cysts were treated with shunts, a cyst-to-pleural space shunt in two and a cyst-to-subarachnoid space shunt in one. All of the patients either improved or exhibited an arrest in the progression of their symptoms. Spinal arachnoid cysts are a treatable cause of progressive neurological deficits and, in this series, were frequently found in patients with neural tube defects.
39
Asaadi, Erfan, and P. Stephan Heyns. "Flow stress identification of tubular materials using the progressive inverse identification method." Engineering Computations 33, no. 5 (July 4, 2016): 1472–89. http://dx.doi.org/10.1108/ec-08-2015-0219.
Full textAbstract:
Purpose – The purpose of this paper is to propose a progressive inverse identification algorithm to characterize flow stress of tubular materials from the material response, independent of choosing an a priori hardening constitutive model. Design/methodology/approach – In contrast to the conventional forward flow stress identification methods, the flow stress is characterized by a multi-linear curve rather than a limited number of hardening model parameters. The proposed algorithm optimizes the slopes and lengths of the curve increments simultaneously. The objective of the optimization is that the finite element (FE) simulation response of the test estimates the material response within a predefined accuracy. Findings – The authors employ the algorithm to identify flow stress of a 304 stainless steel tube in a tube bulge test as an example to illustrate application of the algorithm. Comparing response of the FE simulation using the obtained flow stress with the material response shows that the method can accurately determine the flow stress of the tube. Practical implications – The obtained flow stress can be employed for more accurate FE simulation of the metal forming processes as the material behaviour can be characterized in a similar state of stress as the target metal forming process. Moreover, since there is no need for a priori choosing the hardening model, there is no risk for choosing an improper hardening model, which in turn facilitates solving the inverse problem. Originality/value – The proposed algorithm is more efficient than the conventional inverse flow stress identification methods. In the latter, each attempt to select a more accurate hardening model, if it is available, result in constructing an entirely new inverse problem. However, this problem is avoided in the proposed algorithm.
40
Tan, Zhu Hua, Bo Zhang, and Peng Cheng Zhai. "The Buckling Mechanism of Square Tube Subjected to the Impact of a Mass." Applied Mechanics and Materials 624 (August 2014): 267–71. http://dx.doi.org/10.4028/www.scientific.net/amm.624.267.
Full textAbstract:
The dynamic response of the square tube subjected to the impact of a mass was investigated by using experimental and numerical methods. The square tube was impacted by a mass at the velocity ranging from 5.09 m/s to 12.78 m/s, and different progressive buckling modes were obtained. The numerical simulation was also carried out to analyze the buckling mechanism of the square tube. The results show that there is obvious stress wave propagation and strain localization in the tube, which has a significant influence on the buckling mechanism of the tube. The stress wave and inertia of the mass play different roles at various impact velocities. And buckling mechanism at low velocity is mainly caused by stress wave, whereas the buckling mechanism at high velocity is resulted from the inertial of the mass.
41
Mashhadiali, Niloufar, Ali Kheyroddin, and Rouzbeh Zahiri-Hashemi. "Dynamic Increase Factor for Investigation of Progressive Collapse Potential in Tall Tube-Type Buildings." Journal of Performance of Constructed Facilities 30, no. 6 (December 2016): 04016050. http://dx.doi.org/10.1061/(asce)cf.1943-5509.0000905.
Full text
42
Motalebi, Seyedeh Ameneh, and Seng Cheong Loke. "Efficacy of Progressive Resistance Tube Training in Community Dwelling Older Adults: A Pilot Study." International Journal of Gerontology 8, no. 4 (December 2014): 213–18. http://dx.doi.org/10.1016/j.ijge.2013.12.007.
Full text
43
Paleri, Vinidh, Joanne Patterson, Nikki Rousseau, Eoin Moloney, Dawn Craig, Dimitrios Tzelis, Nina Wilkinson, et al. "Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT." Health Technology Assessment 22, no. 16 (April 2018): 1–144. http://dx.doi.org/10.3310/hta22160.
Full textAbstract:
Background Approximately 9000 new cases of head and neck squamous cell cancers (HNSCCs) are treated by the NHS each year. Chemoradiation therapy (CRT) is a commonly used treatment for advanced HNSCC. Approximately 90% of patients undergoing CRT require nutritional support via gastrostomy or nasogastric tube feeding. Long-term dysphagia following CRT is a primary concern for patients. The effect of enteral feeding routes on swallowing function is not well understood, and the two feeding methods have, to date (at the time of writing), not been compared. The aim of this pilot randomised controlled trial (RCT) was to compare these two options. Methods This was a mixed-methods multicentre study to establish the feasibility of a RCT comparing oral feeding plus pre-treatment gastrostomy with oral feeding plus as-required nasogastric tube feeding in patients with HNSCC. Patients were recruited from four tertiary centres treating cancer and randomised to the two arms of the study (using a 1 : 1 ratio). The eligibility criteria were patients with advanced-staged HNSCC who were suitable for primary CRT with curative intent and who presented with no swallowing problems. Main outcome measures The primary outcome was the willingness to be randomised. A qualitative process evaluation was conducted alongside an economic modelling exercise. The criteria for progression to a Phase III trial were based on a hypothesised recruitment rate of at least 50%, collection of outcome measures in at least 80% of those recruited and an economic value-of-information analysis for cost-effectiveness. Results Of the 75 patients approached about the trial, only 17 consented to be randomised [0.23, 95% confidence interval (CI) 0.13 to 0.32]. Among those who were randomised, the compliance rate was high (0.94, 95% CI 0.83 to 1.05). Retention rates were high at completion of treatment (0.94, 95% CI 0.83 to 1.05), at the 3-month follow-up (0.88, 95% CI 0.73 to 1.04) and at the 6-month follow-up (0.88, 95% CI 0.73 to 1.04). No serious adverse events were recorded in relation to the trial. The qualitative substudy identified several factors that had an impact on recruitment, many of which are amenable to change. These included organisational factors, changing cancer treatments and patient and clinician preferences. A key reason for the differential recruitment between sites was the degree to which the multidisciplinary team gave a consistent demonstration of equipoise at all patient interactions at which supplementary feeding was discussed. An exploratory economic model generated from published evidence and expert opinion suggests that, over the 6-month model time horizon, pre-treatment gastrostomy tube feeding is not a cost-effective option, although this should be interpreted with caution and we recommend that this should not form the basis for policy. The economic value-of-information analysis indicates that additional research to eliminate uncertainty around model parameters is highly likely to be cost-effective. Study limitations The recruitment issues identified for this cohort may not be applicable to other populations undergoing CRT. There remains substantial uncertainty in the economic evaluation. Conclusions The trial did not meet one of the three criteria for progression, as the recruitment rate was lower than hypothesised. Once patients were recruited to the trial, compliance and retention in the trial were both high. The implementation of organisational and operational measures can increase the numbers recruited. The economic analysis suggests that further research in this area is likely to be cost-effective. Future work The implementation of organisational and operational measures can increase recruitment. The appropriate research question and design of a future study needs to be identified. More work is needed to understand the experiences of nasogastric tube feeding in patients undergoing CRT. Trial registration Current Controlled Trials ISRCTN48569216. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 16. See the NIHR Journals Library website for further project information.
44
Minotti, P., P. Le Moal, L. Buchaillot, and A. Ferreira. "Moteurs piézo-électriques à onde progressive : I. Modélisation de la conversion d'énergie mécanique à l'interface stator/rotor." Journal de Physique III 6, no. 10 (October 1996): 1315–37. http://dx.doi.org/10.1051/jp3:1996189.
Full text
45
Ferreira, A., P. Cusin, P. Minotti, and P. Le Moal. "Moteurs piézo-électriques à onde progressive : III. Limites de validité des modèles 2-D et perspectives actuelles." Journal de Physique III 6, no. 10 (October 1996): 1363–88. http://dx.doi.org/10.1051/jp3:1996191.
Full text
46
Hwang, S. F., and H. L. Yu. "Impact Fracture of Polymer-Filled Braided Composite Tubes." Journal of Mechanics 36, no. 3 (December 2, 2019): 305–13. http://dx.doi.org/10.1017/jmech.2019.44.
Full textAbstract:
ABSTRACTThree types of polymer including polyurethane, polyethylene, and polysulfone were used as filler inside composite tubes to evaluate their effects on the crashworthiness. The composite tube consisting of carbon fiber fabric and polyurethane was fabricated by resin transfer molding and subjected to impact loading. In addition, the finite element analysis with progressive failure and delamination was used to simulate the crushing behavior of the polymer-filled composite tube. From the comparison between experiment and simulation, the finite element analysis is reliable, could reasonably describe the crushing behavior of the polymer-filled tube, and has nice prediction on the crashworthiness performance. From both the experiment and simulation results, the polyethylene-filled composite tube has clearly higher specific absorbed energy than the hollow composite tube, and polyethylene could be considered as an effective filler. However, the other two types of polymer filler have no clear effect.
47
Fowler, Nathan, Loretta Nastoupil, Sven de Vos, Mark Knapp, Ian W. Flinn, Robert W. Chen, Ranjana H. Advani, et al. "Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study." Blood 128, no. 22 (December 2, 2016): 1804. http://dx.doi.org/10.1182/blood.v128.22.1804.1804.
Full textAbstract:
Abstract Background: Follicular lymphoma (FL) is the most common subtype of indolent NHL. Current chemoimmunotherapeutic regimens used for FL are not curative. Rituximab (RTX), as a single-agent and in combination with chemotherapy, is a commonly used frontline approach for FL. Ibrutinib (ibr), a first-in-class, once-daily, oral inhibitor of Bruton's tyrosine kinase, showed activity in a phase 1, dose-escalation study in patients (pts) with relapsed/refractory FL, with an overall response rate (ORR) of 38% (Advani, J Clin Oncol 2013). In this phase 2 multicenter, open-label study of ibr combined with RTX, an ORR of 82% and a complete response [CR] rate of 27% for Arm 1 at a median follow-up of 10.2 months (mo) was previously reported (Fowler, ASH 2015). Here, current efficacy and safety results of this study for Arms 1 and 2 using 2 different treatment combination schedules are presented. Methods: Pts with treatment-naïve, histologically confirmed FL (grade 1, 2 and 3a, stage II-IV disease) were administered 1 of 2 treatment combination schedules. In Arm 1, pts received ibr 560 mg once daily until progressive disease (PD) or unacceptable toxicity, combined with RTX 375 mg/m2 IV once weekly for 4 doses for the first 4 weeks of the study. In Arm 2, pts received a lead-in of ibr 560 mg for 8 weeks, and then concurrently with RTX 375 mg/m2 IV once weekly for 4 doses, followed by continuous ibr 560 mg until PD or unacceptable toxicity. The purpose of the Arm 2 design was to identify biomarkers that may predict ibr sensitivity or resistance. The primary endpoint was investigator-assessed ORR (2007 IWG criteria). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Results: Sixty pts were treated in Arm 1 and 20 in Arm 2. Median age was 58 and 55 years in Arm 1 and 2, respectively, ECOG PS1 in 22% and 40% of pts, stage III/IV disease in 80% and 95%, and grade 3a FL in 10% and 5%, respectively. All pts in Arm 1 and 85% in Arm 2 completed the 4-week RTX therapy. Median treatment duration was 20 mo in Arm 1 and 12 mo in Arm 2. At a median time on study of 22 mo for Arm 1, the ORR was 85%, with 35% (21/60) CRs and 50% (30/60) PRs. At a median time on study of 15 mo for Arm 2, the ORR was 75%, with 35% (7/20) CRs and 40% (8/20) PRs. Median time to best response was 2.7 mo for Arm 1, and 4.3 mo for Arm 2. Median DOR, PFS, and OS were not reached in either arm. The 12-mo PFS rates were 87% (Arm 1) and 77% (Arm 2), and the 12-mo OS rates were 98% (Arm 1) and 100% (Arm 2). The most common adverse events (AEs; ≥30%) included fatigue (67%), diarrhea (50%), nausea (47%), constipation (30%), and headache (30%) in Arm 1, and fatigue (75%), diarrhea (60%), nausea (55%), stomatitis (55%), dizziness and myalgia (45% each), paresthesia and maculopapular rash (35% each), and increased lacrimation and upper respiratory tract infection (30%) in Arm 2. Common grade ≥3 AEs in either Arm 1 or 2 (in >5% pts) included maculopapular rash (5% and 10%, respectively), fatigue (7% and 5%), pyrexia (3% and 10%), and diarrhea (Arm 2 only-10%). Serious AEs occurred in 20% of pts, with a higher frequency in Arm 2 vs Arm 1 (25% vs. 18%). Any-grade bleeding was reported in 33% of pts, with only 1 grade 2 bleeding event of petechiae in Arm 1, and 1 grade 3 event of rectal hemorrhage in Arm 2; all other bleeding events were grade 1. Any-grade atrial fibrillation occurred in 4 pts (all in Arm 1), leading to treatment discontinuation in 2 pts. Secondary malignancies were reported in 4 pts (3 in Arm 1 and 1 in Arm 2): Hodgkin's lymphoma (n=1; grade 3 and 5); fallopian tube cancer (n=1; grade 3); basal cell carcinoma (n=1; grade 2); and lung adenocarcinoma (n=1; grade 2). Overall, 40% of pts in Arm 1 discontinued ibr (progressive disease [PD]: 13%; AEs: 15%, pt decision: 7%; and investigator decision: 5%); 60% continued treatment. In Arm 2, 30% of pts discontinued ibr (PD: 20%; AEs: 10%); 70% of pts continued treatment. Conclusions:In treatment-naïve pts with FL, ibr combined with 4 cycles of RTX continues to demonstrate robust clinical activity and durable responses, with a high ORR. In addition, the responses appear to improve over time with a higher CR rate observed with longer follow-up in this report (Arm 1). The study treatment was well tolerated, and no new/increased safety signals were observed with additional follow-up, with AEs being primarily grade 1-2 and as expected based on the experience with single-agent ibr and previously tested ibr and RTX combinations. Disclosures Fowler: Pharmacyclics, LLC, an AbbVie Company: Consultancy, Research Funding; Janssen: Consultancy, Research Funding. Nastoupil:AbbVie: Research Funding; Janssen: Other: Travel, Accommodations, Expenses, Research Funding; TG Therapeutics: Research Funding; Celgene: Honoraria. Knapp:Insys Therapeutics, Inc.: Consultancy, Other: Travel, Accommodations, Expenses; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding. Flinn:Janssen: Research Funding; Pharmacyclics LLC, an AbbVie Company: Research Funding; Gilead Sciences: Research Funding; ARIAD: Research Funding; RainTree Oncology Services: Equity Ownership. Chen:Seattle Genetics: Consultancy, Honoraria, Research Funding, Speakers Bureau; Millenium: Consultancy, Research Funding, Speakers Bureau; Genentech: Consultancy, Speakers Bureau; Merck: Consultancy, Research Funding. Bhatia:CHOP, LLC: Employment, Other: Leadership; Pfizer: Honoraria. Martin:Gilead: Consultancy, Other: travel, accommodations, expenses; Janssen: Consultancy, Honoraria, Other: travel, accommodations, expenses; Novartis: Consultancy; Teva: Research Funding; Celgene: Consultancy, Honoraria; Acerta: Consultancy. Suzuki:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment, Other: Leadership; Travel, Accommodations, Expenses. Beaupre:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment, Other: Leadership, Patents & Royalties, Research Funding. Neuenburg:AbbVie: Equity Ownership; Pharmacyclics, LLC, an AbbVie Company: Employment. Palomba:Juno: Consultancy; Janssen: Consultancy.
48
Canon, E., L. Jouneau, T. Blachère, N. Peynot, N. Daniel, L. Boulanger, L. Maulny, et al. "Progressive methylation of POU5F1 regulatory regions during blastocyst development." Reproduction 156, no. 2 (August 2018): 145–61. http://dx.doi.org/10.1530/rep-17-0689.
Full textAbstract:
ThePOU5F1gene encodes one of the ‘core’ transcription factors necessary to establish and maintain pluripotency in mammals. Its function depends on its precise level of expression, so its transcription has to be tightly regulated. To date, few conserved functional elements have been identified in its 5′ regulatory region: a distal and a proximal enhancer, and a minimal promoter, epigenetic modifications of which interfere withPOU5F1expression and function inin vitro-derived cell lines. Also, its permanent inactivation in differentiated cells depends onde novomethylation of its promoter. However, little is known about the epigenetic regulation ofPOU5F1expression in the embryo itself. We used the rabbit blastocyst as a model to analyze the methylation dynamics of thePOU5F15′ upstream region, relative to its regulated expression in different compartments of the blastocyst over a 2-day period of development. We evidenced progressive methylation of the 5′ regulatory region and the first exon accompanying differentiation and the gradual repression ofPOU5F1. Methylation started in the early trophectoderm before complete transcriptional inactivation. Interestingly, the distal enhancer, which is known to be active in naïve pluripotent cells only, retained a very low level of methylation in primed pluripotent epiblasts and remained less methylated in differentiated compartments than the proximal enhancer. This detailed study identified CpGs with the greatest variations in methylation, as well as groups of CpGs showing a highly correlated behavior, during differentiation. Moreover, our findings evidenced few CpGs with very specific behavior during this period of development.
49
Piura, B., and A. Rabinovich. "Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma." International Journal of Gynecologic Cancer 15, no. 4 (2005): 612–17. http://dx.doi.org/10.1136/ijgc-00009577-200507000-00006.
Full textAbstract:
Topotecan has demonstrated antitumor activity in heavily pretreated patients with ovarian carcinoma. This report examines the activity and toxicity of topotecan in 29 heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma. Topotecan 1.5 mg/m2 was administered intravenously on days 1–5, every 21 days. It was second-line chemotherapy in 6 (20.7%) patients, third-line in 15 (51.7%), fourth-line in 4 (13.8%), fifth-line in 3 (10.3%), and seventh-line in 1 (3.4%). Median dose intensity was 1.667 mg/m2/week, and median relative dose intensity was 0.67. Disease complete response was observed in 5 (17.2%) patients, partial response in 1 (3.4%), stable disease in 12 (41.4%), and progressive disease in 11 (37.9%). CA-125 complete response was observed in 3 (10.3%) patients, partial response in 11 (37.9%), stable level in 5 (17.2%), and progressive level in 9 (31%), and no data were available in 1 (3.4%) patient. Toxicity was mainly hematologic: grade 3–4 neutropenia was observed in 20 (69%) patients, grade 3–4 leukopenia in 12 (41.4%), grade 3–4 thrombocytopenia in 9 (31%), and grade 3–4 anemia in 2 (6.9%). It is concluded that topotecan has considerable activity and noncumulative hematologic toxicity in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
50
Jiang, Hongyong, Yiru Ren, and Jianqiang Zheng. "Gradient-degraded material-induced trigger to improve crashworthiness of composite tubes in a controlled manner." Journal of Reinforced Plastics and Composites 39, no. 1-2 (September 2, 2019): 60–77. http://dx.doi.org/10.1177/0731684419872004.
Full textAbstract:
A type of gradient-degraded material-induced trigger has a greater potential to induce a progressive crushing mode in a controlled manner to reduce the initial crushing load and increase the specific energy absorption. Thus, different material degradation strategy-based triggers are designed to improve the crashworthiness of composite tubes. To understand the triggering mechanisms, effects of height of trigger and level of degradation are studied using single material degradation strategies. In turn, gradient material degradation strategies are novelly presented to explore different crushing behaviors of tube. Further, an improved gradient material degradation gathering all features of single material degradation and gradient material degradation is proposed. The virtual quasi-static crushing tests are conducted where the model considers intra-ply and inter-ply failure initiation and damage evolution. The crushing behaviors of all triggered tubes are compared. From the predicted results, it is found that both the height of trigger and level of degradation have significant effects on the crushing behavior. The multi-phased or progressive initial crushing process is presented by using gradient material degradation. By comparison, the tube using the improved gradient material degradation presents 8.26% lower peak load, 8.75% higher specific energy absorption, and 25% higher crushing load stability than the original tube.